166
Participants
Start Date
February 29, 2008
Primary Completion Date
February 28, 2009
Study Completion Date
February 28, 2009
Erlotinib + Sorafenib
Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
Erlotinib + Placebo
Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
Center for Cancer and Blood Disorders, Bethesda
Virginia Cancer Institute, Richmond
Cancer Care of Western North Carolina, Asheville
South Carolina Oncology Associates, PA, Columbia
Wellstar Cancer Research, Marietta
Northeast Georgia Medical Center, Gainesville
Florida Cancer Specialists, Fort Myers
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Family Cancer Center, Collierville
Mid Ohio Oncology/Hematology, Inc./ The Mark H. Zangmeister Center, Columbus
Oncology Hematology Care, Cincinnati
Grand Rapids Clinical Oncology Program, Grand Rapids
Kansas City Cancer Centers, Overland Park
Methodist Cancer Center, Omaha
Coastal Bend Cancer Center, Corpus Christi
Collaborators (1)
Bayer
INDUSTRY
SCRI Development Innovations, LLC
OTHER